Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
27,850
+400 (1.46%)
At close: Mar 21, 2025, 3:30 PM KST
-16.49%
Market Cap 379.12B
Revenue (ttm) n/a
Net Income (ttm) -38.24B
Shares Out 14.20M
EPS (ttm) -2,736.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,616
Average Volume 64,318
Open 26,900
Previous Close 27,450
Day's Range 26,600 - 28,200
52-Week Range 19,390 - 38,500
Beta n/a
RSI 35.65
Earnings Date Apr 3, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.